MedPharm and Tergus Pharma Merge to Create Topical & Transdermal CDMO Leader

Ampersand Capital Partners Acquires Purna Pharmaceuticals

February 12, 2026

Pharmaceuticals

Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider of liquid and semi-solid pharmaceutical dosage forms. The investment positions Purna to collaborate with Ampersand portfolio company MedPharm to create a trans‑Atlantic topical and transdermal development and manufacturing offering; Creafund, Purna's prior investor, supported the company for more than a decade and was referenced in the transaction announcement.

Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies

December 13, 2022

Medical Devices

Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.

TandemAI Merges with Perpetual Medicines to Expand Peptide and AI Drug Discovery Capabilities

July 10, 2025

Biotechnology

TandemAI and Perpetual Medicines have merged, with the combined company operating under the TandemAI name. Perpetual Medicines will operate as a separate entity within TandemAI to extend the firm's capabilities into computational peptide design and integrated synthesis, while leadership from both companies will continue in senior roles; financial terms were not disclosed.

Ampersand Capital Partners Acquires Nektar Therapeutics' PEG Reagent Manufacturing Business, Launches Gannet BioChem

December 2, 2024

Biotechnology

Ampersand Capital Partners has completed the acquisition of Nektar Therapeutics' PEGylation reagent manufacturing business and launched the new Ampersand portfolio company, Gannet BioChem, operating from a 124,000 sq. ft. FDA‑inspected facility in Huntsville, Alabama. The transaction represents a divestiture by Nektar and creates an independent specialty CDMO focused on development, scaling, and GMP production of polyethylene glycol (PEG) reagents for clinical and commercial biopharmaceutical customers.

CGE Partners Invests in Datapharm

February 28, 2022

Pharmaceuticals

CGE Partners has made a growth investment in Datapharm, the UK-based provider of regulatory-driven medicines information and software (including the electronic medicines compendium, emc). The investment will partner with Datapharm's management to accelerate new product development, international expansion, and support strategic acquisitions.

Montagu Private Equity Acquires Tyber Medical, Combining It with Resolve and Intech

April 8, 2025

Medical Devices

Montagu Private Equity has acquired Tyber Medical, LLC and combined it with its existing portfolio companies Resolve Surgical Technologies and Intech to form an integrated medical device solutions provider. The transaction, which closed on April 8, 2025, creates a next-generation, global orthopedic device development and manufacturing platform offering private-label implantable devices, instrumentation, design, regulatory and advanced manufacturing capabilities.